Science Explorer Interactive view Map
Topic · Complementary and alternative medicine

Nigella sativa pharmacological applications

Nigella sativa pharmacological applications is a research topic within Complementary and alternative medicine. Science Explorer counts 5.7k research works in it since 1951. 24.7% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the therapeutic potential of Nigella sativa, focusing on its antioxidant, anti-inflammatory, immunomodulatory, and anticancer properties. The research covers the pharmacological and toxicological properties of Nigella sativa, as well as the effects of its active component, thymoquinone, on various health conditions such as cancer, diabetes, and neurodegenerative diseases.

  • Nigella sativa
  • Thymoquinone
  • Antioxidant
  • Anti-inflammatory
  • Cancer
  • Immunomodulatory
  • Pharmacological properties
  • Toxicological properties
  • Hepatoprotective effects
  • Anticancer activity
Research works
5.7k
fractional, since 1951
In the world top 10%
1.4k
per year above
Top-10% rate
24.7%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+84%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Nigella sativa pharmacological applications research?

By volume, India and Indonesia publish the most (276 and 173 works in 2022–2025).

By volume, 2022–2025

  1. 1 India 276 works
  2. 2 Indonesia 173 works
  3. 3 Egypt 161 works
  4. 4 Türkiye 150 works
  5. 5 Iran 148 works
  6. 6 Saudi Arabia 87 works
  7. 7 China 81 works
  8. 8 Nigeria 74 works
  9. 9 Iraq 74 works
  10. 10 Pakistan 67 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

India: 21.4%Indonesia: 13.4%Egypt: 12.5%Türkiye: 11.6%6 others listed: 41.1%21%largest
India276 · 21.4%Indonesia173 · 13.4%Egypt161 · 12.5%Türkiye150 · 11.6%6 others listed531 · 41.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Nigella sativa pharmacological applications research?

By volume in 2022–2025, Cairo University publishes the most Nigella sativa pharmacological applications research, followed by King Saud University and Airlangga University.

By volume, 2022–2025

  1. 1 Cairo UniversityEgypt 14 works
  2. 2 King Saud UniversitySaudi Arabia 14 works
  3. 3 Airlangga UniversityIndonesia 13 works
  4. 4 Ain Shams UniversityEgypt 11 works
  5. 5 King Abdulaziz UniversitySaudi Arabia 10 works
  6. 6 Zagazig UniversityEgypt 10 works
  7. 7 University of BaghdadIraq 10 works
  8. 8 Al-Azhar UniversityEgypt 10 works
  9. 9 University of BrawijayaIndonesia 10 works
  10. 10 Benha UniversityEgypt 9 works

Where is Nigella sativa pharmacological applications research done?

The largest centres of Nigella sativa pharmacological applications research in 2022–2025 are Cairo (Egypt), Tehran (Iran), Giza (Egypt) and Riyadh (Saudi Arabia). Among places with at least 20 works in it, it is an unusually large share of all research in Giza.

Largest cities, 2022–2025

  1. 1 Cairo Egypt 38 works
  2. 2 Tehran Iran 38 works
  3. 3 Giza Egypt 31 works
  4. 4 Riyadh Saudi Arabia 26 works
  5. 5 Chennai India 22 works
  6. 6 Baghdad Iraq 21 works
  7. 7 Surabaya Indonesia 20 works
  8. 8 Istanbul Türkiye 19 works
  9. 9 New Delhi India 18 works
  10. 10 Lahore Pakistan 18 works

Where it is the local speciality

  1. GizaEG · 30.7 works13×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Nigella sativa pharmacological applications than the world average.

See Nigella sativa pharmacological applications on the map

Where is the best place to study Nigella sativa pharmacological applications?

Among universities, judged by research, King Saud University, Cairo University and Al-Azhar University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.87%fractional works in this node (log) →share in the world top 10% →King Saud University: 14, 37.8%Cairo University: 14, 17.1%Al-Azhar University: 10, 27.3%King Abdulaziz University: 10, 17.7%Mashhad University of Medical Sciences: 9, 33.4%Ain Shams University: 11, 18.7%Zagazig University: 10, 20.8%Assiut University: 8, 17.4%Benha University: 9, 7.6%Airlangga University: 13, 0.9%King Saud UniversityAl-Azhar UniversityKing Abdulaziz Unive…Cairo University
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 King Saud UniversitySaudi Arabia 81.037.8%9.5×14 -26.0%
2 Cairo UniversityEgypt 65.817.1%11.3×14 +27.6%
3 Al-Azhar UniversityEgypt 65.727.3%15.3×10 +96.0%
4 King Abdulaziz UniversitySaudi Arabia 63.717.7%11.5×10 +119.0%
5 Mashhad University of Medical SciencesIran 62.133.4%23.6×9 +61.1%
6 Ain Shams UniversityEgypt 59.018.7%9.8×11 +89.3%
7 Zagazig UniversityEgypt 56.320.8%16.4×10 +35.0%
8 Assiut UniversityEgypt 44.717.4%19.1×8 -19.9%
9 Benha UniversityEgypt 43.17.6%17.8×9 —
10 Airlangga UniversityIndonesia 39.90.9%8.8×13 —

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Nigella sativa pharmacological applications research growing?

Output in 2018–2022 was 84% higher than in 2013–2017, peaking in 2021. The fastest-growing topics are Nigella sativa pharmacological applications.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.